Literature DB >> 26632545

Immunotherapy for hepatocellular carcinoma.

Shuzhan Li1, Fan Yang, Xiubao Ren.   

Abstract

Hepatocellular carcinoma (HCC) is the most common type of hepatic malignancies, with poor prognosis. Treatment for HCC are limited, especially for patients with advanced disease who are not eligible for curative hepatectomy or hepatic transplantation. Mechanisms of immune response during tumor development have been investigated for decades. The efficacy and safety of immunotherapy have also been tested in clinical treatment of malignancies. Here we reviewed the immunotherapy strategies for HCC, as well as the particularity of liver immune system and the immune tolerance of HCC. Vaccines, adaptive therapy, immune checkpoint blockades and cytokines are included. We hope this review will give us an integral concept on HCC immunotherapy and help the readers to understand the mechanism of immune tolerance in liver cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26632545     DOI: 10.5582/ddt.2015.01054

Source DB:  PubMed          Journal:  Drug Discov Ther        ISSN: 1881-7831


  35 in total

1.  [Identification of onco-miRNAs in hepatocellular carcinoma and analysis of their regulatory network].

Authors:  J Ye; W Xu; T Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-01-20

2.  LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.

Authors:  Jianwu Long; Longfei Liu; Xuefeng Yang; Xiaojun Zhou; Xianzhou Lu; Lei Qin
Journal:  Hum Cell       Date:  2022-10-15       Impact factor: 4.374

3.  Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis.

Authors:  Jianguo Zhang; Jianzhong Zhang; Cheng Yuan; Yuan Luo; Yangyi Li; Panpan Dai; Wenjie Sun; Nannan Zhang; Jiangbo Ren; Junhong Zhang; Yan Gong; Conghua Xie
Journal:  Cancer Cell Int       Date:  2020-07-20       Impact factor: 5.722

Review 4.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

Review 5.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12

6.  Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Lejia Sun; Gang Xu; Wenjun Liao; Huayu Yang; Haifeng Xu; Shunda Du; Haitao Zhao; Xin Lu; Xinting Sang; Yilei Mao
Journal:  Oncotarget       Date:  2017-06-13

7.  High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients.

Authors:  Li Peng; Xiao-Qing Yuan; Chao-Yang Zhang; Fei Ye; Hui-Fang Zhou; Wen-Ling Li; Zhao-Yang Liu; Ya-Qin Zhang; Xi Pan; Guan-Cheng Li
Journal:  Oncotarget       Date:  2017-05-23

Review 8.  An updated systematic review of the evolution of ALPPS and evaluation of its advantages and disadvantages in accordance with current evidence.

Authors:  Yu-Long Cai; Pei-Pei Song; Wei Tang; Nan-Sheng Cheng
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.

Authors:  Yue Zhao; Timothy Wai Ho Shuen; Tan Boon Toh; Xue Ying Chan; Min Liu; Sue Yee Tan; Yong Fan; Hechuan Yang; Shridhar Ganpathi Lyer; Glenn Kunnath Bonney; Eva Loh; Kenneth Tou En Chang; Thiam Chye Tan; Weiwei Zhai; Jerry Kok Yen Chan; Edward Kai-Hua Chow; Cheng Ean Chee; Guan Huei Lee; Yock Young Dan; Pierce Kah-Hoe Chow; Han Chong Toh; Seng Gee Lim; Qingfeng Chen
Journal:  Gut       Date:  2018-03-30       Impact factor: 23.059

10.  Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway.

Authors:  Junfeng Ye; Di Sun; Ying Yu; Jinhai Yu
Journal:  Aging (Albany NY)       Date:  2020-07-16       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.